Equities

Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)99.00
  • Today's Change-0.80 / -0.80%
  • Shares traded2.58k
  • 1 Year change+117.11%
  • Beta0.8116
Data delayed at least 15 minutes, as of Jun 14 2024 17:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-128.42m
  • Incorporated2011
  • Employees9.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Intellego Technologies AB223.23m81.38m704.93m62.008.713.628.213.163.073.078.537.390.90875.242.823,600,549.0033.13--46.94--68.45--36.46--2.137.890.1833--222.74--493.56------
Moberg Pharma AB (publ)820.00k-22.56m729.50m9.00--1.19--889.64-1.09-1.090.037921.630.0014--0.2841---3.81---3.96--60.00---2,751.22--1.73--0.0073---100.00---34.26------
Nightingale Health Oyj41.11m-203.18m745.57m81.00--1.11--18.14-0.2979-0.29790.06031.500.03441.603.8744,560.98-17.02-14.20-18.12-15.6975.8183.57-494.25-408.5014.15--0.0378--80.8019.05-12.38------
Orexo AB619.10m-73.40m782.72m113.00--12.65134.951.26-2.13-2.1317.981.780.69591.082.535,337,069.00-8.25-6.41-20.27-9.9988.1486.76-11.86-11.830.5890.13860.8948--2.32-3.9927.76--25.77--
Alligator Bioscience AB55.49m-248.80m864.16m55.00------15.57-0.4848-0.48480.0999-0.07720.5289--8.07956,741.40-237.13-73.26---91.33-----448.35-811.68---104.20----62.7816.60-28.53---20.34--
Cantargia AB0.00-241.07m916.60m23.00--6.89-----1.40-1.400.000.72390.00----0.00-83.14-55.08-107.52-61.35------------0.00------24.69------
BioPorto A/S48.84m-81.18m956.34m27.00--15.20--19.58-0.1501-0.15010.09030.10990.41323.667.331,044,452.00-68.68-71.10-100.20-96.5568.0863.38-166.23-239.222.36--0.1354--6.873.5425.81---51.56--
Vistin Pharma ASA431.00m55.29m972.33m77.0017.593.3313.352.261.271.279.886.701.112.317.445,692,663.0014.281.7318.932.1159.9358.9212.832.360.853632.960.0934--51.3516.951,066.84---0.1922--
SyntheticMR AB (publ)90.86m15.67m1.18bn38.0074.669.8553.5713.030.38040.38042.212.880.6719--1.582,455,541.0011.597.1913.878.8573.9469.7017.259.08----0.008321.5030.6713.0570.34-7.3327.30--
Cereno Scientific AB0.00-59.13m1.19bn5.00--4.93-----0.281-0.2810.000.85980.00----0.00-24.71-16.81-26.65-18.26-----------10.700.1843-------73.95--44.79--
Arcticzymes Technologies ASA115.77m17.26m1.23bn68.0071.443.9952.4910.630.34430.34432.306.170.35620.42286.291,731,471.005.3115.585.6617.2295.5096.6914.9133.2312.14--0.03270.00-13.1612.24-40.89--47.93--
Infant Bacterial Therapeutics AB0.00-128.42m1.29bn9.00--4.81-----9.96-9.960.0020.590.00----0.00-37.63-16.11-43.78-16.69------------0.00-------88.03------
Diamyd Medical AB282.00k-120.18m1.37bn26.00--7.39--4,841.36-1.41-1.410.00331.910.0014--6.5611,280.00-59.77-25.46-66.19-28.37-4,930.85-1,419.23-42,617.73-5,896.43---130.780.1176--20.26-5.54-12.13------
Photocure ASA503.87m4.74m1.72bn102.00368.203.6252.893.420.17550.175519.0217.820.72150.91447.935,024,010.000.6789-3.060.7682-3.5494.6593.640.941-5.154.33--0.00--27.3522.50101.36--49.83--
Nanoform Finland Oyj27.27m-261.38m1.78bn166.00--2.40--65.37-0.2974-0.29740.0310.7740.0287100.584.2914,687.82-27.47-27.13-30.12-29.48-576.50-604.26-958.65-1,023.706.60--0.091---26.4161.315.98--53.92--
Devyser Diagnostics AB180.50m-45.90m1.81bn124.00--4.83--10.01-2.83-2.8311.1323.000.36711.565.111,529,661.00-9.33-8.97-10.65-10.1584.7680.14-25.43-23.914.34--0.1543--33.7128.59-16.64--44.59--
Data as of Jun 14 2024. Currency figures normalised to Infant Bacterial Therapeutics AB's reporting currency: Swedish Krona SEK

Institutional shareholders

38.51%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 07 May 20241.34m10.32%
Keel Capital ABas of 08 Jan 2024666.05k5.12%
AMF Fonder ABas of 07 May 2024601.90k4.62%
Premier Fund Managers Ltd.as of 30 Nov 2023581.73k4.47%
Tredje AP-fondenas of 07 May 2024523.37k4.02%
SEB Investment Management ABas of 31 Dec 2023443.25k3.41%
�landsbanken Fondbolag AB (Sweden)as of 07 May 2024409.52k3.15%
Banque Pictet & Cie SA (Investment Management)as of 07 May 2024311.17k2.39%
Handelsbanken Fonder ABas of 31 May 202481.31k0.63%
Tiff Advisory Services LLCas of 31 Mar 202450.19k0.39%
More ▼
Data from 29 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.